1. Home
  2. NBTB vs IMNM Comparison

NBTB vs IMNM Comparison

Compare NBTB & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NBTB

NBT Bancorp Inc.

HOLD

Current Price

$42.63

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$21.75

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBTB
IMNM
Founded
1856
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NBTB
IMNM
Price
$42.63
$21.75
Analyst Decision
Buy
Strong Buy
Analyst Count
2
9
Target Price
$51.00
$31.44
AVG Volume (30 Days)
227.2K
2.9M
Earning Date
01-26-2026
11-06-2025
Dividend Yield
3.47%
N/A
EPS Growth
5.89
N/A
EPS
3.02
N/A
Revenue
$629,728,000.00
$9,679,000.00
Revenue This Year
$27.08
N/A
Revenue Next Year
$9.17
$11.53
P/E Ratio
$14.14
N/A
Revenue Growth
16.88
N/A
52 Week Low
$37.31
$5.15
52 Week High
$49.43
$25.30

Technical Indicators

Market Signals
Indicator
NBTB
IMNM
Relative Strength Index (RSI) 47.60 58.53
Support Level $42.31 $21.33
Resistance Level $42.91 $22.57
Average True Range (ATR) 0.97 1.44
MACD -0.20 0.01
Stochastic Oscillator 30.97 48.23

Price Performance

Historical Comparison
NBTB
IMNM

About NBTB NBT Bancorp Inc.

NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Share on Social Networks: